Profile of pomalidomide and its potential in the treatment of myelofibrosis

References

• TefferiAPathogenesis of myelofibrosis with myeloid metaplasiaJ Clin Oncol200523338520853016293880
   PubMed Web of Science ®Google Scholar
• SchmittAJouaultHGuichardJWendlingFDrouinACramerEMPathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosisBlood20009641342134710942376
   PubMed Web of Science ®Google Scholar
• XuMBrunoEChaoJConstitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteasesBlood2005105114508451515705794
   PubMed Web of Science ®Google Scholar
• TefferiAPrimary myelofibrosis: 2014 update on diagnosis, risk-stratification, and managementAm J Hematol201489991592525124313
   PubMed Web of Science ®Google Scholar
• MesaRANiblackJWadleighMThe burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patientsCancer20071091687617123268
   PubMed Web of Science ®Google Scholar
• BirgegardGDoes anything work for anaemia in myelofibrosis?Best Pract Res Clin Haematol201427217518525189728
   PubMed Web of Science ®Google Scholar
• CervantesFDupriezBPereiraANew prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and TreatmentBlood2009113132895290118988864
   PubMed Web of Science ®Google Scholar
• KrogerNHollerEKobbeGAllogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationBlood2009114265264527019812383
   PubMed Web of Science ®Google Scholar
• TefferiASilversteinMNRecombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasiaBr J Haematol19948648937918092
   PubMed Web of Science ®Google Scholar
• TefferiAElliotMAYoonSYClinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasiaBlood2001976189611263440
   PubMed Web of Science ®Google Scholar
• HasselbalchHCClausenNTJensenBASuccessful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietinAm J Hematol2002702929912111781
   PubMed Web of Science ®Google Scholar
• Martinez-TrillosAGayaAMaffioliMEfficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patientsAnn Hematol201089121233123720567824
   PubMed Web of Science ®Google Scholar
• CervantesFMesaRBarosiGNew and old treatment modalities in primary myelofibrosisCancer J200713637738318032975
   PubMed Web of Science ®Google Scholar
• SinghPPTimucinTNagorneyDMTefferiASplenectomy for massive splenomegaly associated with myelofibrosis: outcomes from 63 patients at Mayo ClinicASH Annual Meeting Abstracts2012120212848
   Google Scholar
• PardananiABrownPNeben-WittichMTobinRTefferiAEffective management of accelerated phase myelofibrosis with low-dose splenic radiotherapyAm J Hematol201085971571620661915
   PubMed Web of Science ®Google Scholar
• MesaRAHow I treat symptomatic splenomegaly in patients with myelofibrosisBlood2009113225394540019332765
   PubMed Web of Science ®Google Scholar
• BarosiGElliottMCanepaLThalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studiesLeuk Lymphoma200243122301230712613516
   PubMed Web of Science ®Google Scholar
• KiladjianJJCassinatBChevretSPegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia veraBlood200811283065307218650451
   PubMed Web of Science ®Google Scholar
• LevineRLWadleighMCoolsJActivating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell20057438739715837627
   PubMed Web of Science ®Google Scholar
• JamesCUgoVLe CouedicJPA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature200543470371144114815793561
   PubMed Web of Science ®Google Scholar
• SantosFPSVerstovsekSBreakthroughs in myeloproliferative neoplasmsHematology201217Suppl 1S55S5822507780
   PubMedGoogle Scholar
• HarrisonCKiladjianJJAl-AliHKJAK inhibition with ruxolitinib versus best available therapy for myelofibrosisN Engl J Med2012366978779822375970
   PubMed Web of Science ®Google Scholar
• CervantesFVannucchiAMKiladjianJJThree-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosisBlood2013122254047405324174625
   PubMed Web of Science ®Google Scholar
• GowinKMesaREmerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosisExpert Opin Investig Drugs2013221216031611
   PubMed Web of Science ®Google Scholar
• AzimaHArthursDControl study of thalidomide (Kevadon), a new hypnotic agentAm J Psychiatry196111855455513863556
   PubMed Web of Science ®Google Scholar
• SomersGSThalidomide and congenital abnormalitiesLancet19621723591291313915092
   PubMed Web of Science ®Google Scholar
• D’AmatoRJLoughnanMSFlynnEFolkmanJThalidomide is an inhibitor of angiogenesisProc Natl Acad Sci U S A1994919408240857513432
   PubMed Web of Science ®Google Scholar
• SinghalSMehtaJDesikanRAntitumor activity of thalidomide in refractory multiple myelomaN Engl J Med1999341211565157110564685
   PubMed Web of Science ®Google Scholar
• TefferiASerious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasiaBlood20009612400711186278
   PubMed Web of Science ®Google Scholar
• BarosiGGrossiAComottiBMustoPGambaGMarchettiMSafety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasiaBr J Haematol20011141788311472348
   PubMed Web of Science ®Google Scholar
• CanepaLBalleriniFVaraldoRThalidomide in agnogenic and secondary myelofibrosisBr J Haematol2001115231331511703326
   PubMed Web of Science ®Google Scholar
• PozzatoGZoratFNascimbenFComarCKikicFFestiniGThalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasiaHaematologica200186777277311454539
   PubMed Web of Science ®Google Scholar
• ElliottMAMesaRALiCYThalidomide treatment in myelofibrosis with myeloid metaplasiaBr J Haematol2002117228829611972510
   PubMed Web of Science ®Google Scholar
• MesaRASteensmaDPPardananiAA phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasiaBlood200310172534254112517815
   PubMed Web of Science ®Google Scholar
• MarchettiMBarosiGBalestriFLow-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trialJ Clin Oncol200422342443114752066
   PubMed Web of Science ®Google Scholar
• MesaRAElliottMASchroederGTefferiADurable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasiaMayo Clin Proc200479788388915244384
   PubMed Web of Science ®Google Scholar
• SilverRTMyelofibrosis: thalidomide finds a new diseaseMayo Clin Proc200479785785815244380
   PubMed Web of Science ®Google Scholar
• StruppCGermingUSchererAThalidomide for the treatment of idiopathic myelofibrosisEur J Haematol2004721525714962263
   PubMed Web of Science ®Google Scholar
• AbgrallJ-FGuibaudIBastieJ-NThalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter studyHaematologica20069181027103216885042
   PubMed Web of Science ®Google Scholar
• ThomasDAGilesFJAlbitarMThalidomide therapy for myelofibrosis with myeloid metaplasiaCancer200610691974198416583431
   PubMed Web of Science ®Google Scholar
• BerrebiAFeldbergESpivakIShvidelLMini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegalyHaematologica2007922e15e1617405746
   PubMed Web of Science ®Google Scholar
• WeinkoveRReillyJTMcMullinMFCurtinNJRadiaDHarrisonCNLow-dose thalidomide in myelofibrosisHaematologica20089371100110118508796
   PubMed Web of Science ®Google Scholar
• KohKRJanzMMaparaMYImmunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesisBlood2005105103833384015292067
   PubMed Web of Science ®Google Scholar
• LentzschSLeBlancRPodarKImmunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivoLeukemia2003171414412529658
   PubMed Web of Science ®Google Scholar
• ChamberlainPPLopez-GironaAMillerKStructure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogsNat Struct Mol Biol201421980380925108355
   PubMed Web of Science ®Google Scholar
• AndersonKCPrinceHMLenalidomide and thalidomide: an evolving paradigm for the management of multiple myelomaSemin Hematol2005424 Suppl 4S1S216344096
   PubMed Web of Science ®Google Scholar
• BladeJRosinolLFernandez de LarreaCHow I treat relapsed myelomaBlood1132015 Epub ahead of print
   Google Scholar
• TefferiACortesJVerstovsekSLenalidomide therapy in myelofibrosis with myeloid metaplasiaBlood200610841158116416609064
   PubMed Web of Science ®Google Scholar
• TefferiALashoTLMesaRAPardananiAKetterlingRPHansonCALenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissionsLeukemia20072181827182817460705
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHMManshouriTLenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosisJ Clin Oncol200927284760476619720904
   PubMed Web of Science ®Google Scholar
• StreetlyMJGyertsonKDanielYZeldisJBKazmiMScheySAAlternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulationBr J Haematol20081411415118324965
   PubMed Web of Science ®Google Scholar
• LacyMQRajkumarSVPomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosisAm J Hematol2010852959620095057
   PubMed Web of Science ®Google Scholar
• TefferiAVerstovsekSBarosiGPomalidomide is active in the treatment of anemia associated with myelofibrosisJ Clin Oncol200927274563456919652059
   PubMed Web of Science ®Google Scholar
• MesaRAPardananiADHusseinKPhase 1/-2 study of pomalidomide in myelofibrosisAm J Hematol201085212913020052748
   PubMed Web of Science ®Google Scholar
• BegnaKHMesaRAPardananiAA phase-2 trial of low-dose pomalidomide in myelofibrosisLeukemia201125230130421052089
   PubMed Web of Science ®Google Scholar
• BegnaKHPardananiAMesaRLong-term outcome of pomalidomide therapy in myelofibrosisAm J Hematol2012871666822081489
   PubMed Web of Science ®Google Scholar
• DaverNShastriAKadiaTModest activity of pomalidomide in patients with myelofibrosis and significant anemiaLeuk Res201337111440144423890523
   PubMed Web of Science ®Google Scholar
• DaverNShastriAKadiaTPhase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemiaLeuk Res20143891126112925047979
   PubMed Web of Science ®Google Scholar
• TefferiAPassamontiFBarbuiGPhase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)-associated myelofibrosis with RBC-transfusion-dependencePresented at the American Society of Hematology 55th Annual MeetingDecember 7–10, 2013New Orleans, LA, USA
   Google Scholar
• StefelmannFReiterAA multicenter Phase-Ib/II study of ruxolitinib/pomalidomide combination therapy in patients with primary and secondary myelofibrosis: safety data from the MPNSG-0212 trialPresented at the American Society of Hematology 56th Annual MeetingDecember 6–9, 2014San Francisco, CA, USA
   Google Scholar
• VerstovsekSRuxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosisPostgrad Med2013125112813523391678
   PubMed Web of Science ®Google Scholar